The Acumen Standard
Beyond the exam. Better at every rung.
An examination sets the floor of competence, not the ceiling of care. MD Acumen teaches every learner, from the first clinical year to advanced postgraduate study, to the same standard: know the medicine, weigh the evidence, and see what actually happens to patients. Then close the gap.
Medical school Graduate and GP trainee Advanced practice Reviewed and kept current
Last editorial review: 7 October 2026 · Next scheduled refresh: 7 January 2027.
Passing is necessary. It is not the point.
Every examination in medicine, from finals to PLAB 2 to the MRCGP, tests a safe minimum. Patients need more than a safe minimum. They need a doctor who knows the condition precisely, who knows what the best evidence says and where it runs out, and who notices when the care a patient receives falls short of the care the guideline describes.
That third skill is rarely taught and never examined. It is where character, ethics and equity enter medicine: where the evidence stops, judgement begins. MD Acumen teaches all three, at every stage of a career, with one method.
Precision
Learning tied to the current named guideline and its version, so what you learn is what is true today, not what was true when a textbook went to press.
Judgement
Practice in the decisions the evidence does not settle: competing priorities, uncertainty, and the patient in front of you who is not the patient in the trial.
Character
Attention to who misses out on care, and why, and a sense of duty to do something about it in the consulting room, the practice and the wider system.
Three questions for every condition
The Golden Triangle is a dated snapshot of a condition, in a setting, seen through three lenses: what is known, what should be done, and what actually happens. Its aim is the Equinox: the point at which all three corners are Green and the triangle turns golden. A golden triangle means the delivery of effective, best-evidence precision medicine for the individual, in their healthcare setting. It is the ambition of every clinician, and it has been achieved for very few conditions.
Below is the blank triangle: the framework before any condition is applied. Its corners are black, and each holds a question.
What is known?
How it presents, how it is diagnosed, how it works and how it is treated. The corner a textbook covers.
Informed by: published clinical knowledge.
What should be done?
Guidelines, trials and the national position, and how strong they are: best care for the ideal patient in the ideal setting.
Informed by: guidelines, randomised controlled trials and meta-analyses, weighed by the strength of the evidence.
What actually happens?
Uptake, access and outcomes by postcode, sex, ethnicity and deprivation. This corner also carries ethics and character: the tools for responding to the gap.
Informed by: real-world health epidemiology, public health data and the influence of national health policy.
Rating each corner for a condition
When a condition is taught, its triangle is built for that condition in that setting, and each corner is rated. The rating records what the sources show today, and the diagram shows where work is still needed. The pull is that work: drawing each corner in toward the Equinox.
Established
Well understood, well evidenced or well delivered. No arrow: nothing more needs drawing in from this corner.
Partly established
Some certainty, with real gaps. One arrow runs from the corner to the Equinox: more work is needed.
A gap
Uncertain, unproven or unequal. Two arrows run from the corner to the Equinox: much more work is needed.
Until all three corners are Green, the triangle stays white. When all three are Green, it turns golden: thin lines draw every corner into the centre, and the letter E marks the Equinox.
From the blank triangle to the Equinox
No condition
Osteoporosis, UK
SGLT2 inhibitors in heart failure, UK
The Equinox
The Equinox: the golden triangle
The Equinox is the centre of the triangle and the aim of the whole framework: the point of equilibrium between knowledge, evidence and the real world. A condition reaches it when Knowledge, Evidence and Real-world are all Green, and the triangle turns golden.
A golden triangle, at the Equinox, means the delivery of effective, best-evidence precision medicine for the individual, in their healthcare setting.
The ambition of every clinician
The clinician stands at the centre, not as a spectator but as a force: turning each corner Green and pulling all three in together, through the consultation, the practice team, specialist colleagues, community services and, where needed, the system itself.
Achieved for very few conditions
Most triangles are still white, with at least one arrow pointing in. That is worth knowing: the arrows show exactly where a better doctor, and a better health system, still have work to do.
A snapshot at the time of teaching
A condition's triangle is the best available framework of that disorder on the date the topic is created or taught. It is never timeless: each triangle is dated and cites its sources, and when the knowledge, the evidence or the epidemiology and policy change, the ratings are re-examined and the triangle is re-dated (see the Living Curriculum).
The rating and the pull
The rating records what the sources show today, and changes only when they change. The pull is what the clinician does: closing the gap for the patient in front of them now, and helping to move the rating over time through research, audit, teaching and advocacy.
Why equilateral. An equilateral triangle is the one triangle in which every definition of the centre falls on the same point. Equal sides are equity. Knowledge, Evidence and Real-world carry equal weight, so the Equinox sits exactly at the centre, the same distance from each. No corner can be left behind: the triangle turns golden only when all three arrive together.
| ● Green | ● Amber | ● Red | |
|---|---|---|---|
| What the rating means | Established: little further need | Partly established: real gaps remain | A gap: the priority for further work |
| Knowledge | Presentation, diagnosis and mechanism well characterised | Partly understood; diagnosis difficult or variable | Poorly understood; unusual presentation |
| Evidence | Robust trials; licensed, effective treatments | Limited or weak evidence; no specific treatment | Evidence absent or contradictory |
| Real-world | No material barriers to access; outcomes do not vary by group | Delays or variation by area, without a social gradient | Marked inequity of access or outcome by deprivation, sex, ethnicity or geography |
| What the learner does | Apply it with confidence, for every patient | Weigh it case by case, and explain the uncertainty to patients | Act on the gap: refer, advocate, audit and improve the service |
The definitions, in one place
| Term | Definition |
|---|---|
| The Golden Triangle | A dated snapshot of a condition, in a setting, seen through three lenses: Knowledge, Evidence and Real-world. |
| Knowledge (top) | What is known: published clinical knowledge of how the condition presents, works, is diagnosed and is treated. |
| Evidence (bottom left) | What should be done: guidelines, randomised controlled trials and meta-analyses, weighed by the strength of the evidence. |
| Real-world (bottom right) | What actually happens: real-world health epidemiology, public health data and the influence of national health policy. |
| The blank triangle | The framework before any condition is applied: black corners, each holding a question. |
| The rating | Each corner rated Green (established, no arrow), Amber (partly established, one arrow) or Red (a gap, two arrows), as the sources show on the date of the snapshot. |
| The pull | The work of drawing each corner in toward the Equinox: for the patient now, and for the rating over time. |
| The Equinox | All three corners Green: the triangle turns golden, its corners are drawn into the centre, and E marks the Equinox. It means the delivery of effective, best-evidence precision medicine for the individual, in their healthcare setting. The ambition of every clinician; achieved for very few conditions. |
Osteoporosis and fragility fracture, UK
Here the blank triangle is rated for one condition: each corner takes its colour, and arrows show where more work is needed. Knowledge is Amber, Evidence is Amber and Real-world is Red: treatment works, but finding the people who need it is less certain, and the care they receive depends on where they live.
Risk is more than bone density: most fragility fractures occur with a T-score above −2.5, and vertebral fractures often go undiagnosed.
Drug treatment reduces fractures: alendronate, risedronate and zoledronate reduce vertebral, non-vertebral and hip fractures. But evidence for how best to find and assess people at risk in primary care is limited. NICE NG259 (July 2026) sets risk and DXA criteria.
Hip fracture is 1.50 times more common in the most deprived men than the least deprived, and 1.17 times in women. Fracture Liaison Services cover 63% of hospitals; treatment is recommended for 52% of the most deprived patients against 58% of the least.
The pull. Assess everyone NG259 names with FRAX or QFracture; use the FRAX model for a migrant's country of birth; give every fragility fracture a Fracture Liaison Service; audit assessment and treatment by group.
Reflect. In your own practice or placement, who with a fragility fracture is least likely to be assessed, and what one change would reach them?
Sources: NICE NG259, Osteoporosis: risk assessment (29 July 2026); NOGG clinical guideline (2024, updated December 2024); Bhimjiyani A, et al. Osteoporos Int 2018;29:115–24; Royal College of Physicians, FLS-DB annual report (January 2026). Ratings confirmed by the Director, 8 October 2026 (Evidence revised from Green to Amber).
SGLT2 inhibitors in chronic heart failure, UK
A contrast. Knowledge is Green and Evidence is Green: what the condition is, and what should be done, are settled. Real-world is Amber: whether every eligible patient actually receives the treatment still depends on where they live and how their care has been recorded.
Heart failure is diagnosed with NT-proBNP, ECG and echocardiography, and NICE classifies it by ejection fraction: HFrEF ≤40%, HFmrEF 41–49% and HFpEF ≥50%.
NICE offers the four pillars of treatment in HFrEF, an SGLT2 inhibitor among them (NG106, rec 1.4.1). The 2026 ESC guideline recommends an SGLT2 inhibitor in symptomatic heart failure at any ejection fraction (class I, level A).
Legacy prescribing disparities persist, and the coding and case ascertainment that identify eligible patients vary by geography.
The pull. Search practice registers for people with HFrEF who are not on all four pillars, and check that heart failure is coded so that eligible patients can be found.
Reflect. In your own practice or placement, which patients with heart failure were started on treatment before SGLT2 inhibitors were recommended, and has anyone reviewed them since?
The Equinox: the triangle turns golden
When all three corners are Green, the triangle turns golden and the corners are drawn into the centre: effective, best-evidence precision medicine for the individual, in their healthcare setting. For SGLT2 inhibitors in heart failure, the knowledge and the evidence are settled, but the real world is not yet Green, so the triangle stays white with one arrow in. The golden triangle is the ambition of every clinician, and it has been achieved for very few conditions.
Sources: NICE NG106, Chronic heart failure in adults: diagnosis and management (updated 3 September 2025); Køber L, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J 2026 (published 28 August 2026). Ratings set by the Director, 8 October 2026.
Taught as it is today, and kept that way
Every clinical statement is signed by a named GMC-registered clinician with the date and the guideline version relied on. Nothing reaches a learner unsigned. AI assists the drafting of our material, and no AI decides a mark.
Medicine changes faster than courses do. Every MD Acumen teaching page names the guideline and the version it was checked against, carries the date it was last reviewed, and is reviewed again when the guidance changes, not when a print run ends.
NICE NG12 replaced a single CA125 cut-off with age-specific thresholds and an ultrasound-first route under 40. Our women's health teaching has been updated to match.
NICE NG23 defined when unscheduled bleeding is expected and pointed to the British Menopause Society's risk-based pathway. Our menopause teaching now uses it, instead of referring every bleed.
An amending regulation moved the dates on which the EU AI Act's high-risk rules apply to medical devices. Our European policy teaching shows both the original and the new dates, as a lesson in why currency matters.
One school, every stage of a medical career
The same method runs from the first clinical year to advanced practice. Each stage builds on the one before, and every page shows where you came from and where you can go next.
Medical students
European core ECTS modules, a four-week UK primary care observership, and Acumen Ascent for building a portfolio.
Graduates and IMGs
A free PLAB 2 OSCE course with 20 practice cases and mark schemes, live classes, and a roadmap to UK practice.
GP trainees
An MRCGP SCA course with full stations, and courses delivered for the Royal College of General Practitioners.
Practising clinicians
Certificates of Advanced Studies, masterclasses and micro-learning for GPs and the wider primary care team.
What you will find on every MD Acumen teaching page
1 · The case
A patient first: a short clinical scenario that makes the topic real before any theory.
2 · The Golden Triangle
Knowledge, Evidence and Real-world for that condition, each rated, with the pull toward the Equinox.
3 · Kept current
The guideline and version checked, the date of review and the date of the next one.
4 · Reflect
One private question about your own practice: what would you do differently tomorrow?
5 · The level
The academic level the teaching is pitched at, aligned to the FHEQ level descriptors.
6 · Where next
The stage below and the stage above, so learning carries forward across a career.
One standard, one signature
Every clinical statement in MD Acumen teaching cites a named, dated source. Every lesson and assessment item on the MD Acumen learning platform is checked and signed by the Director, Professor Rajesh Varma, before learners see it, and re-checked when its sources change. Every public teaching page shows when it was last reviewed. MD Acumen is a teaching authority, not an awarding authority: academic credit is awarded by partner universities only where a page states it.
© 2026 MD Acumen Ltd · Registered in England and Wales · Company no. 16538952 · ICO registration ZC105897